Pancreatic neuroendocrine tumors and <i>MUTYH</i> pathogenic variants: a multinational study
<i>MUTYH</i> mutation-associated PanNET (germline and/or somatic) is associated with aggressive and high-grade disease when metastatic.
Authors
- Tiago Cordeiro Felismino (ORCID: https://orcid.org/0000-0002-1055-8118)
- Halfdan Sørbye (ORCID: https://orcid.org/0000-0002-7132-6214)
- Sara Cingarlini (ORCID: https://orcid.org/0000-0003-4786-4781)
- Emily K. Bergsland (ORCID: https://orcid.org/0000-0001-7754-6552)
- Farhana Moon
- Giovana Tardin Torrezan (ORCID: https://orcid.org/0000-0002-8659-5329)
- Nitya Raj (ORCID: https://orcid.org/0000-0002-1385-9995)
- Rachel P. Riechelmann (ORCID: https://orcid.org/0000-0002-0107-9617)
- Stian Knappskog (ORCID: https://orcid.org/0000-0002-4153-1655)
- Jonathan Strosberg (ORCID: https://orcid.org/0000-0001-8405-218X)
- Elena Trevizani
Institutions
- University of Verona (IT)
- Memorial Sloan Kettering Cancer Center (US)
- University of California, San Francisco (US)
- Haukeland University Hospital (NO)
- AC Camargo Hospital (BR)
- Moffitt Cancer Center (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- University of Bergen (NO)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359251356335
- Citations
- 2
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 2.71